| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2025 | Dec, 2025 | Dec, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -50,370 | -22,300 | 0 | 0 | 0 |
| Net Income Growth | -125.87% | unch | unch | unch | unch |
Cincor Pharma Inc (CINC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CinCor Pharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CinCor Pharma Inc. is based in BOSTON.
Fiscal Year End Date: 12/31